Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etoposide Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.83 |
| ▸ | LMNA | P02545 | 6/20 | 0.83 |
| ▸ | GAA | P10253 | 5/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.83 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.83 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.83 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etoposide Phosphate SCHEMBL3621 | 1.00 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL1649994 | 1.00 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL15118344 | 1.00 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL13524290 | 1.00 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL29564759 | 1.00 | CYP3A4 (0.83) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| SCHEMBL15395274 | 0.96 | CYP3A4 (0.81) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| SCHEMBL8727825 | 0.95 | CYP3A4 (0.80) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL13318140 | 0.95 | CYP3A4 (0.75) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| SCHEMBL13524695 | 0.95 | CYP3A4 (0.75) | CYP3A4LMNAGAASMN1; SMN2TOP2A | |
| Etoposide Phosphate SCHEMBL13318121 | 0.94 | CYP3A4 (0.74) | CYP3A4LMNAGAASMN1; SMN2TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10354 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622976-B2 | Targeting CLPTM1L for treatment and prevention of cancer | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260083867-A1 | METHODS AND REAGENTS FOR TUMOR TARGETING WITH GREATER EFFICACY AND LESS TOXICITY | UNIV CORNELL (US) | 2026-03-26 | — | — | US | claimed |
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4711364-A1 | FUSED PYRROLE RING OR FUSED PYRIDINE RING COMPOUND | Pharmaengine, Inc. (TW) | 2026-03-18 | — | — | EP | claimed |
| EP-4701737-A2 | MTA-COOPERATIVE PRMT5 INHIBITOR | Pharmaengine, Inc. (TW) | 2026-03-04 | — | — | EP | claimed |
| US-20260049111-A1 | METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER | MULTIVIR INC. (US) | 2026-02-19 | — | — | US | claimed |
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2026-02-05 | — | — | US | claimed |
| US-20250345444-A1 | CLEAVABLE FRAGMENT DIRECTED BY AFFINITY FRAGMENT, DESIGN AND SYNTHESIS THEREOF, AND USE THEREOF IN PREPARATION OF SITE-DIRECTED DRUG CONJUGATE | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2025-11-13 | — | — | US | claimed |
| US-20250275938-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | SCIROSBIO LIMITED (AE) | 2025-09-04 | — | — | US | claimed |
| US-20250276084-A1 | HYDROPHILIC LINKERS AND CONJUGATES THEREOF | GLYKOS FINLAND OY (FI) | 2025-09-04 | — | — | US | claimed |
| US-11311548-B2 | Cancer therapy | ASLAN PHARMACEUTICALS PTE. LTD. (SG) | 2022-04-26 | — | — | US | claimed |
| US-11311613-B2 | Development of agonist epitopes of the human papillomavirus | The United States of Americans represented by the Secretary, Department of Health and Human Services (US) | 2022-04-26 | — | — | US | claimed |
| US-20220117990-A1 | KRAS ANTAGONISTS | TRUETIVA, Inc. (US) | 2022-04-21 | — | — | US | claimed |
| US-20220117894-A1 | TARGETED POLYMERIZED NANOPARTICLES FOR CANCER TREATMENT | CHILDREN'S HOSPITAL LOS ANGELES (US) | 2022-04-21 | — | — | US | claimed |
| WO-2022081521-A1 | INOSITOL-BISPYROPHOSPHATE-DERIVED COMPOUNDS AND USES THEREOF | NICOLAU YVES CLAUDE (US) | 2022-04-21 | — | — | WO | claimed |
| CN-114364377-A | Methods useful for treating cancers with KRAS or HRAS mutations or amplifications | 纪念斯隆凯特琳癌症中心 | 2022-04-15 | — | — | CN | claimed |
| US-20220111060-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | UNIV YALE (US) | 2022-04-14 | — | — | US | claimed |
| WO-2022072293-A2 | METHODS AND COMPOSITIONS FOR SYNERGISTIC UPTAKE AND RETENTION OF SMALL MOLECULE LIGANDS | CORNELL UNIVERSITY (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022047375-A1 | NOVEL FUNGAL MODULATORS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-03 | — | — | WO | claimed |
| US-20220023428-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | claimed |